Covert Hepatic Encephalopathy: Not as Minimal as You Might Think

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 11, 2012, Pages 1208-1219

  Kappus, Matthew R ^a   Bajaj, Jasmohan S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cirrhosis; Cognition; Liver disease; Management; Minimal hepatic encephalopathy

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCARNITINE; ACETYLCHOLINESTERASE; AMMONIA; ANTIBIOTIC AGENT; BROMOCRIPTINE; FLUMAZENIL; INTERLEUKIN 1; INTERLEUKIN 6; LACTULOSE; LEVODOPA; NALOXONE; PROBIOTIC AGENT; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA;

CRITICAL FLICKER FUSION; DRIVING ABILITY; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; FALLING; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATION; PATHOGENESIS; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; SOCIAL STATUS; SURVIVAL;

GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER DISEASES; PSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84867664455     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.05.026     Document Type: Review

References (134)

1. Bajaj J.S., Wade J.B., Sanyal A.J. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50:2014-2021.
2. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification-final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
3. Ortiz M., Jacas C., Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005, 42(Suppl):S45-S53.
4. Bajaj J.S., Cordoba J., Mullen K.D., et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011, 33:739-747.
5. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9.
6. Bajaj J.S., Saeian K., Verber M.D., et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007, 102:754-760.
7. Ford J.M., Gray M., Whitfield S.L., et al. Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 2004, 61:119-129.
8. Schiff S., Vallesi A., Mapelli D., et al. Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 2005, 20:381-392.
9. Weissenborn K., Ennen J.C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
10. Bajaj J.S., Hafeezullah M., Franco J., et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008, 135:1591-1600.
11. Córdoba J., Cabrera J., Lataif L., et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998, 27:339-345.
12. Franco R.A., Ashwathnarayan R., Deshpandee A., et al. The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice. J Clin Sleep Med 2008, 4:45-49.
13. Martino M.E., Romero-Vives M., Fernández-Lorente J., et al. Sleep electroencephalogram alterations disclose initial stage of encephalopathy. Methods Find Exp Clin Pharmacol 2002, 24(Suppl D):119-122.
14. Mostacci B., Ferlisi M., Baldi Antognini A., et al. Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study. Neurol Sci 2008, 29:237-240.
15. Ahboucha S., Butterworth R.F. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2008, 52:575-587.
16. Ahboucha S., Butterworth R.F. The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy. Metab Brain Dis 2007, 22:291-308.
17. Norenberg M.D., Jayakumar A.R., Rama Rao K.V., et al. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis 2007, 22:219-234.
18. Schliess F., Görg B., Häussinger D. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. Biol Chem 2006, 387:1363-1370.
19. Shawcross D.L., Davies N.A., Williams R., et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004, 40:247-254.
20. Shawcross D.L., Shabbir S.S., Taylor N.J., et al. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010, 51:1062-1069.
21. Shawcross D.L., Sharifi Y., Canavan J.B., et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011, 54:640-649.
22. Wright G., Shawcross D., Olde Damink S.W., et al. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007, 22:375-388.
23. Lockwood A.H., Yap E.W., Rhoades H.M., et al. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 1991, 11:331-336.
24. Lockwood A.H., Yap E.W., Wong W.H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991, 11:337-341.
25. Cooper A.J., Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987, 67:440-519.
26. Zieve L. Pathogenesis of hepatic encephalopathy. Metab Brain Dis 1987, 2:147-165.
27. Nance F.C., Batson R.C., Kline D.G. Ammonia production in germ-free Eck fistula dogs. Surgery 1971, 70:169-174.
28. Weber F.L., Veach G.L. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979, 77:235-240.
29. Plauth M., Roske A.E., Romaniuk P., et al. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 2000, 46:849-855.
30. Romero-Gómez M., Ramos-Guerrero R., Grande L., et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004, 41:49-54.
31. Romero-Gómez M., Jover M., Del Campo J.A., et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010, 153:281-288.
32. Romero-Gomez M., Jover M., Diaz-Gomez D., et al. Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. World J Gastroenterol 2006, 12:2406-2411.
33. Olde Damink S.W., Jalan R., Redhead D.N., et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002, 36:1163-1171.
34. Thomas J.W., Banner C., Whitman J., et al. Changes in glutamate-cycle enzyme mRNA levels in a rat model of hepatic encephalopathy. Metab Brain Dis 1988, 3:81-90.
35. Cooper A.J., McDonald J.M., Gelbard A.S., et al. The metabolic fate of 13N-labeled ammonia in rat brain. J Biol Chem 1979, 254:4982-4992.
36. Häussinger D., Kircheis G., Fischer R., et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000, 32:1035-1038.
37. Córdoba J., Sanpedro F., Alonso J., et al. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002, 17:415-429.
38. Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006, 43:1187-1190.
39. Rovira A., Alonso J., Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 2008, 29:1612-1621.
40. Shawcross D.L., Balata S., Olde Damink S.W., et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol 2004, 287:G503-G509.
41. Butterworth R.F. Pathophysiology of hepatic encephalopathy: the concept of synergism. Hepatol Res 2008, 38:S116-S121.
42. Gregorios J.B., Mozes L.W., Norenberg L.O., et al. Morphologic effects of ammonia on primary astrocyte cultures: I-light microscopic studies. J Neuropathol Exp Neurol 1985, 44:397-403.
43. Blei A.T. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 2004, 40:327-330.
44. Pedersen H.R., Ring-Larsen H., Olsen N.V., et al. Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital. J Hepatol 2007, 47:245-252.
45. Vaquero J., Chung C., Blei A.T. Brain edema in acute liver failure: a window to the pathogenesis of hepatic encephalopathy. Ann Hepatol 2003, 2:12-22.
46. Shawcross D.L., Wright G., Olde Damink S.W., et al. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007, 22:125-138.
47. Moldawer L.L., Marano M.A., Wei H., et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989, 3:1637-1643.
48. Didier N., Romero I.A., Créminon C., et al. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003, 86:246-254.
49. de Vries H.E., Blom-Roosemalen M.C., van Oosten M., et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996, 64:37-43.
50. Duchini A., Govindarajan S., Santucci M., et al. Effects of tumor necrosis factor-alpha and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells. J Investig Med 1996, 44:474-482.
51. Norenberg M.D., Itzhak Y., Bender A.S. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997, 420:95-111.
52. Mullen K.D., Szauter K.M., Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990, 336:81-83.
53. Baraldi M., Avallone R., Corsi L., et al. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. Metab Brain Dis 2009, 24:81-93.
54. Ahboucha S., Butterworth R.F. Role of endogenous benzodiazepine ligands and their GABA-A-associated receptors in hepatic encephalopathy. Metab Brain Dis 2005, 20:425-437.
55. Butterworth R.F., Tonon M.C., Désy L., et al. Increased brain content of the endogenous benzodiazepine receptor ligand octadecaneuropeptide (ODN), following portacaval anastomosis in the rat. Peptides 1991, 12:119-125.
56. Hernández-Avila C.A., Shoemaker W.J., Ortega-Soto H.A. Plasma concentrations of endogenous benzodiazepine-receptor ligands in patients with hepatic encephalopathy: a comparative study. J Psychiatry Neurosci 1998, 23:217-222.
57. Olasmaa M., Rothstein J.D., Guidotti A., et al. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem 1990, 55:2015-2023.
58. García-Ayllón M.S., Cauli O., Silveyra M.X., et al. Brain cholinergic impairment in liver failure. Brain 2008, 131:2946-2956.
59. Méndez M., Méndez-López M., López L., et al. Acetylcholinesterase activity in an experimental rat model of type C hepatic encephalopathy. Acta Histochem 2011, 113:358-362.
60. García-Ayllón M.S., Silveyra M.X., Candela A., et al. Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology 2006, 43:444-453.
61. Groeneweg M., Quero J.C., De Bruijn I., et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28:45-49.
62. Arguedas M.R., DeLawrence T.G., McGuire B.M. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003, 48:1622-1626.
63. Hartmann I.J., Groeneweg M., Quero J.C., et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000, 95:2029-2034.
64. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001, 16:37-41.
65. Stewart C.A., Smith G.E. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol 2007, 4:677-685.
66. Bajaj J.S., Wade J.B., Gibson D.P., et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011, 106:1646-1653.
67. Schomerus H., Hamster W., Blunck H., et al. Latent portasystemic encephalopathy: I-nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981, 26:622-630.
68. Watanabe A., Tuchida T., Yata Y., et al. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 1995, 10:239-248.
69. Srivastava A., Mehta R., Rothke S.P., et al. Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J Hepatol 1994, 21:1023-1028.
70. Wein C., Koch H., Popp B., et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004, 39:739-745.
71. Kircheis G., Knoche A., Hilger N., et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009, 137:1706-1715.
72. Baskin-Bey E.S., Stewart C.A., Mitchell M.M., et al. Preliminary report of the Hepatic Encephalopathy Assessment Driving Simulator (HEADS) score. Ethn Dis 2008, 18:357-364.
73. Kim Y., Park G., Lee M., et al. Impairment of driving ability and neuropsychological function in patients with MHE disease. Cyberpsychol Behav 2009, 12:433-436.
74. Bajaj J.S., Hafeezullah M., Hoffmann R.G., et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008, 47:596-604.
75. Weissenborn K., Giewekemeyer K., Heidenreich S., et al. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005, 20:359-367.
76. Bajaj J.S., Hafeezullah M., Zadvornova Y., et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009, 104:898-905.
77. Amodio P., Schiff S., Del Piccolo F., et al. Attention dysfunction in cirrhotic patients: an inquiry on the role of executive control, attention orienting and focusing. Metab Brain Dis 2005, 20:115-127.
78. Bajaj J.S., Saeian K., Christensen K.M., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-1715.
79. Bajaj J.S., Saeian K., Hafeezullah M., et al. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol 2008, 6:1135-1139.
80. Bajaj J.S., Saeian K., Schubert C.M., et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009, 50:1175-1183.
81. Gad Y.Z., Zaher A.A., Moussa N.H., et al. Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab Journal of Gastroenterology 2011, 12:58-61.
82. Román E., Córdoba J., Torrens M., et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011, 106:476-482.
83. Soriano G., Roman E., Cordoba J., et al. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology 2011, 55:1922-1930.
84. Amodio P., Del Piccolo F., Marchetti P., et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999, 29:1662-1667.
85. Dhiman R.K., Kurmi R., Thumburu K.K., et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010, 55:2381-2390.
86. Saxena N., Bhatia M., Joshi Y.K., et al. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 2002, 22:190-197.
87. Vergara-Gómez M., Flavià-Olivella M., Gil-Prades M., et al. Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists. Gastroenterol Hepatol 2006, 29:1-6.
88. Bajaj J.S., Etemadian A., Hafeezullah M., et al. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. Hepatology 2007, 45:833-834.
89. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology 1977, 72:573-583.
90. Ortiz M., Córdoba J., Doval E., et al. Development of a clinical hepatic encephalopathy staging scale. Alim Pharmacol Ther 2007, 26:859-867.
91. Hassanein T.I., Hilsabeck R.C., Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci 2008, 53:529-538.
92. Amodio P., Campagna F., Olianas S., et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score: a neuropsychological and quantified EEG study. J Hepatol 2008, 49:346-353.
93. Romero-Gómez M., Córdoba J., Jover R., et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007, 45:879-885.
94. Riggio O., Ridola L., Pasquale C., et al. A simplified psychometric evaluation for the diagnosis of minimal hepatic encephalopathy. Clin Gastroenterol Hepatol 2011, 9:613-616.
95. Sotil E.U., Gottstein J., Ayala E., et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009, 15:184-192.
96. Randolph C., Hilsabeck R., Kato A., et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009, 29:629-635.
97. Douglass A., Al Mardini H., Record C. Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy. J Hepatol 2001, 34:658-664.
98. Oppong K.N., Al-Mardini H., Thick M., et al. Oral glutamine challenge in cirrhotics pre- and post-liver transplantation: a psychometric and analyzed EEG study. Hepatology 1997, 26:870-876.
99. Rees C.J., Oppong K., Al Mardini H., et al. Effect of l-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000, 47:571-574.
100. Garavan H., Ross T.J., Stein E.A. Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Proc Natl Acad Sci U S A 1999, 96:8301-8306.
101. Konrad K., Gauggel S., Manz A., et al. Inhibitory control in children with traumatic brain injury (TBI) and children with attention deficit/hyperactivity disorder (ADHD). Brain Inj 2000, 14:859-875.
102. Pliszka S.R., Liotti M., Woldorff M.G. Inhibitory control in children with attention-deficit/hyperactivity disorder: event-related potentials identify the processing component and timing of an impaired right-frontal response-inhibition mechanism. Biol Psychiatry 2000, 48:238-246.
103. Ballard J.C. Assessing attention: comparison of response-inhibition and traditional continuous performance tests. J Clin Exp Neuropsychol 2001, 23:331-350.
104. Walker A.J., Shores E.A., Trollor J.N., et al. Neuropsychological functioning of adults with attention deficit hyperactivity disorder. J Clin Exp Neuropsychol 2000, 22:115-124.
105. Bajaj J.S., Heuman D.M., Wade J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140:478-487.
106. Amodio P., Ridola L., Schiff S., et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2010, 139:510-518.
107. Mardini H., Saxby B.K., Record C.O. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008, 135:1582-1590.
108. McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
109. Forton D.M., Thomas H.C., Murphy C.A., et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002, 35:433-439.
110. Wesnes K.A., McKeith I.G., Ferrara R., et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002, 13:183-192.
111. Tsushima M., Tsushima W., Tsushima V., et al. A case control study of ImPACT: a brief and effective web-based neuropsychological assessment battery to diagnose minimal hepatic encephalopathy (mhe). J Hepatol 2010, 52(Suppl 1):S87.
112. Prakash R.K., Chikkanna R., Anna K., et al. USA validated computerized psychometric testing system for the diagnosis of minimal hepatic encephalopathy: at last. Gastroenterology 2012, 142(Suppl 1):S-952.
113. Parsons-Smith B.G., Summerskill W.H., Dawson A.M., et al. The electroencephalograph in liver disease. Lancet 1957, 273:867-871.
114. Montagnese S., Jackson C., Morgan M.Y. Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J Hepatol 2007, 46:447-458.
115. Marchetti P., D'Avanzo C., Orsato R., et al. Electroencephalographyalterations in patients with cirrhosis. Gastroenterology 2011, 141:1680-1689.
116. Kircheis G., Wettstein M., Timmermann L., et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-366.
117. Eckstein A.K., Reichenbach A., Jacobi P., et al. Hepatic retinopathia: changes in retinal function. Vision Res 1997, 37:1699-1706.
118. Reichenbach A., Fuchs U., Kasper M., et al. Hepatic retinopathy: morphological features of retinal glial (Muller) cells accompanying hepatic failure. Acta Neuropathol 1995, 90:273-281.
119. Sharma P., Sharma B.C., Puri V., et al. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007, 47:67-73.
120. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
121. Bajaj J.S., Stein A.C., Dubinsky R.M. What is driving the legal interest in hepatic encephalopathy?. Clin Gastroenterol Hepatol 2011, 9:97-98.
122. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
123. Liu Q., Duan Z.P., Ha D.K., et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
124. Watanabe A., Sakai T., Sato S., et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26:1410-1414.
125. Dhiman R.K., Sawhney M.S., Chawla Y.K., et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000, 45:1549-1552.
126. Häussinger D., Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008, 57:1156-1165.
127. Sidhu S.S., Goyal O., Mishra B.P., et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME trial). Am J Gastroenterol 2011, 106:307-316.
128. Bajaj J.S., Riggio O. Drug therapy: rifaximin. Hepatology 2010, 52:1484-1488.
129. Sharma P., Sharma B.C., Puri V., et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008, 20:506-511.
130. Malaguarnera M., Greco F., Barone G., et al. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007, 52:3259-3265.
131. Lighthouse J., Naito Y., Helmy A., et al. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximin alone and in association with a symbiotic preparation. Hepatol Res 2004, 28:155-160.
132. Shukla S., Shukla A., Mehboob S., et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011, 33:662-671.
133. McGee R.G., Bakens A., Wiley K., et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011, 11. CD008716.
134. Bajaj J.S., Pinkerton S.D., Sanyal A.J., et al. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012, 55:1164-1171.